The most frequently exploited tumor markers;Nejčastěji užívané tumorové markery

Prakticky Lekar

Volumn 84, Issue 11, 2004, Pages 658-661

  Slaměník, Marek ^a,b  

^a Interni Oddeleni Nemocnice Teplice   (Czech Republic)

^b NONE   (Czech Republic)

Author keywords

AFP; CA125; CA15 3; CA19 9; CA72 4; CEA; NSE; SCC; Tumor marker

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CELL ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CYTOKERATIN 19 FRAGMENT; LACTATE DEHYDROGENASE; NEURON SPECIFIC ENOLASE; PROSTATE SPECIFIC ANTIGEN; THYROGLOBULIN; TUMOR MARKER;

ANAMNESIS; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER SCREENING; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE COURSE; HUMAN; PANCREAS CANCER; PATIENT MONITORING; PREDICTION; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; STOMACH CANCER; SURVIVAL RATE; TECHNIQUE;

EID: 10944229681     PISSN: 00326739     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Tachibana, M., Takemoto, Y., Nakashima, Y., et al.: Serum carcinoembryonic antigen as a prognostic factor in resectable gastric cancer. J. Am. Coll. Surg., 1998, 187, 1, p. 64-68.
2. Feuer, J. A., Lush, R. M., Venzon, D., et al.: Elevated carcino-embryonic antigen in patients with androgen-independent prostate cancer. J. Investig. Med., 1998, 46, 2, p. 66-72.
3. Forones, N. M., Tanaka, M.: CEA and CA 19-9 as prognostic indexes in colorectal cancer. Hepatogastroenterology, 1999, 46, 26, p. 905-908.
4. Safi, E., Schlosser, W., Falkenreck, S., et al.: Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterology, 1998, 45, 19, p. 253-259.
5. Montgomery, R. C., Hoffman, J. P., Riley, L. B., et al.: Prediction of recurence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann. Surg. Oncol., 1997, 4, 7, p. 551-556.
6. Nouts, A., Levy, P., Voitot, H., et al.: Diagnostic value of serum CA 19-9 antigen in chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterol. Clin. Biol., 1998, 22, 2, p. 152-159.
7. Gonzales Vitores, A. M., Encabo Duro, G., Bermejo Fraile, B., et al.: Utility of tumor marker CA 72-4 in patients with chronic renal failure. Int. J. Biol. Markers, 1999, 14, 2, p. 118-121.
8. Lopez, J. B., Rozan, G. P., Lakhawani, M. N., et al.: CA 72-4 compared with CEA and CA 19-9 as a marker of some gastrointestinal malignancies. Int. J. Biol. Markers, 1999, 14, 3, p. 172-177.
9. Hammel, P., Voitot, H., Vilgrain, V., et al.: Diagnostic value of CA 72-4 and carcino-embryonic antigen determination in the fluid of pancreatic cystic lesion. Eur. J. Gastroenterol. Hepatol., 1998, 10, 4, p. 345-348.
10. Masopust, J.: Klinická biochemie požadování a hodnocení biochemických vyšetření cast II., vyd. Karolinum, 1998.
11. Seifert, J. K., Junginger, T.: Prognostic factors for cryotherapy of colorectal liver metastases. Eur. J. Surg. Oncol., 2004, 30, 1, p. 34-40.
12. Yamamoto, H., Ueda, Y., Maruyama, T., et al.: A case of CA 19-9 producing transitional cell carcinoma of the ureter. Hinyokika Kiyo., 2003, 49, 9, p. 543-545.
13. Ychou, M., Duffour, J., Kramar, A., et al.: Clinical significance and prognostic value of CA 72-4 compared with CEA and CA 19-9 in patients with gastric cancer. Dis. Markers., 2000, 16, 3-4, p. 105-110.
14. Fayed, S. T., Ahmad, S. M., Kassim, S. K., et al.: The value of CA 125 and CA 72-4 in management of patients with epithelial ovaria cancer. Dis. Markers, 1998, 14, 3, p. 155-160.
15. Meier, W., Baumgartner, L., Stieber, P., et al.: Significance of tumor marker determinations in the primary therapy of ovarian cancer. Anticancer Res., 1997, 17, 4B, p. 2949-2951.
16. Kato, J., Hatori, M., Kokubun, S., et al.: CA 125 Expression in Epithelioid Sarcoma. J. Clin. Oncol., 2004, 1, 34, 3, p. 149-154.